Multi-Domain Protease Inhibitor Protein Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical agents that target multiple proteases often cause side effects due to low specificity, inhibiting unintended proteases and not effectively addressing the activity of multiple detrimental proteases in a single disease state.
Innovation Solution
Development of a protein comprising engineered Kunitz domains with high affinity and specificity for multiple human proteases, linked via a peptide bond or a flexible hydrophilic linker, to inhibit multiple proteases simultaneously without cross-reacting with non-target proteases, thereby reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If low-specificity inhibitors (small molecule inhibitors) are used to inhibit multiple proteases, then the treatment can address multiple proteases in a single disease state, but serious side effects occur due to inhibition of proteases other than the intended targets
Solution Approach 1:
The invention divides the inhibitor into multiple separate domains, each domain being responsible for inhibiting a specific protease target. This segmentation allows each domain to maintain high specificity for its intended target while the complete multi-domain protein provides broad coverage against multiple proteases, thereby avoiding off-target effects that occur with low-specificity small molecule inhibitors.
Solution Approach 2:
Different domains within the protein are engineered to have different specificities for different protease targets. Each domain is locally optimized to recognize and bind to its specific target protease with high affinity and specificity, while other domains handle other targets. This local differentiation of function eliminates cross-reactivity and off-target inhibition.
2Adaptability or versatility
If a single active pharmacologic agent is designed to inhibit two or more proteases, then treatment of multiple or various dysregulated proteases can be achieved, but the agent must maintain high specificity for each target to avoid side effects
Solution Approach 1:
The invention merges multiple separate protease-inhibiting domains into a single polypeptide chain or complex. Each domain is engineered to inhibit a specific protease with high specificity, and when combined, the multi-domain protein provides simultaneous inhibition of multiple proteases. This merging approach allows a single agent to treat multiple dysregulated proteases while maintaining high specificity for each target through the domain-specific design.
3Adaptability or versatility
If multiple domains are combined in a single protein to inhibit different proteases, then high affinity and specificity for multiple targets can be achieved, but the protein structure and stability must be maintained
Solution Approach 1:
Multiple Kunitz domains are nested within a single protein structure, with each domain containing its own protease-inhibiting capability. The domains are arranged in a hierarchical structure where each maintains its functional independence while being part of the overall stable protein architecture. This nesting allows the protein to inhibit multiple proteases while maintaining structural integrity through the organized arrangement of functional domains.
Data Source
AI summary
Proteins including engineered sequences which inhibit proteases are disclosed, including proteins having two or more engineered Kunitz domains, and uses of such proteins.